#VisualAbstract: Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome without serious adverse events
There was a dose-related decrease in disease activity from baseline to 24-weeks for patients on ianalumab compared to placebo. There were no serious adverse events from the maximum dose of 300 mg ianalumab, and it was well tolerated by trial participants. Evidence Rating Level: 1 (Excellent) Study Rundown: Sjögren’s syndrome is an autoimmune disorder which is currently […]
Read More